Xinxing Jihua Group Co., Ltd. is a central enterprise supervised by the State-owned Assets Supervision and Administration Commission of the State Council. It is a large state-owned wholly-owned company integrating asset management, capital operation and production and operation. It was formed by the reorganization and reorganization of the original Production Department of the General Logistics Department of the People's Liberation Army and its military-invested enterprises and institutions under its jurisdiction. The earliest member enterprises were founded in 1911 and have a history of more than a hundred years. The headquarters is located in Beijing CBD Wealth Financial Center .

There are six major business segments including metallurgical casting, light industry and textiles, equipment manufacturing, medical and health, emergency rescue and trade services. They are the world's leading ductile casting pipe industry, the leading munitions of national logistics and military supplies, the leading NTAF Alliance for Disaster Emergency Rescue, and the state-owned enterprise The pioneer in exploring deepening reform; it is a central enterprise with emergency industry as its main business approved by the State-owned Assets Supervision and Administration Commission of the State Council, and one of the four central enterprises with pharmaceutical production and trade as its main business.

Shanghai Lishengte Medical Technology Co., Ltd. is a holding subsidiary of Xinxing Jihua Group. It was established in 2004 and is located in Shanghai International Medical Park. It is an innovative high-tech enterprise integrating "production, education, research and medicine". . Relying on the Ophthalmology and Otolaryngology Hospital Affiliated to Fudan University and the Shanghai Institute of Auditology Medicine, the company is committed to the research and development and application of medical devices such as cochlear implants. In 2005, Lishengte launched the earliest cochlear implant product in my country; in 2011, Lishengte was awarded the earliest cochlear implant product registration certificate in China. As of December 31, 2021, there were more than 2,100 cases of LCI-20PI type cochlear implant implants, with a cumulative survival rate of 100%; in 2021, the new generation of cochlear implants, LCI-21PI and The sound processor LSP-20C product is launched and has obtained a medical license for cochlear implant implants for children aged 1-6 years old. At present, the company has obtained 99 national patents, including 20 invention patents, forming the intellectual property rights of cochlear implant technology completely independent.